[1]怡娟,吴天娇,李 玢,等.中晚期宫颈癌介入化疗栓塞术的研究进展成[J].医学信息,2023,36(12):176-180.[doi:10.3969/j.issn.1006-1959.2023.12.037]
 CHENG Yi-juan,WU Tian-jiao,LI Bin,et al.Research Progress of Interventional Chemoembolization for Advanced Cervical Cancer[J].Journal of Medical Information,2023,36(12):176-180.[doi:10.3969/j.issn.1006-1959.2023.12.037]
点击复制

中晚期宫颈癌介入化疗栓塞术的研究进展成()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年12期
页码:
176-180
栏目:
综述
出版日期:
2023-06-15

文章信息/Info

Title:
Research Progress of Interventional Chemoembolization for Advanced Cervical Cancer
文章编号:
1006-1959(2023)12-0176-05
作者:
怡娟吴天娇李 玢
(1.西安医学院研究生处,陕西 西安 710000;2.陕西省人民医院妇产科,陕西 西安 710000)
Author(s):
CHENG Yi-juanWU Tian-jiaoLI Binet al.
(1.Graduate Office of Xi’an Medical University,Xi’an 710000,Shaanxi,China;2.Obstetrics and Gynecology Department of Shaanxi Provincial People’s Hospital,Xi’an 710000,Shaanxi,China)
关键词:
中晚期宫颈癌介入化疗栓塞术新辅助化疗股动脉插管分子通路机制
Keywords:
Advanced cervical cancerInterventional chemoembolizationNeoadjuvant chemotherapyFemoral artery intubationMolecular pathway mechanism
分类号:
R737.33
DOI:
10.3969/j.issn.1006-1959.2023.12.037
文献标志码:
A
摘要:
宫颈癌是妇科最常见的恶性肿瘤,我国宫颈癌的发病率和死亡率相对较高,且呈年轻化的趋势,严重威胁妇女的身心健康。临床上中晚期宫颈癌的治疗原则一般以放疗为主,化疗为辅,但治疗效果欠佳;而介入化疗栓塞术作为一种新的治疗方法,在中晚期宫颈癌的治疗中起到了重要作用,特别是术前新辅助动脉介入化疗具有一定的优势。本文主要就介入化疗栓塞术在中晚期宫颈癌的应用现状及进展进行综述,梳理介入化疗栓塞术在中晚期宫颈癌中的应用进展,以期为临床治疗该病提供参考。
Abstract:
Cervical cancer is the most common malignant tumor in gynecology department. The incidence and mortality of cervical cancer in China are relatively high, and the trend is younger, which seriously threatens the physical and mental health of women. Clinically, the treatment principle of advanced cervical cancer is generally based on radiotherapy, supplemented by chemotherapy, but the treatment effect is not good. As a new treatment method, interventional chemoembolization plays an important role in the treatment of advanced cervical cancer, especially preoperative neoadjuvant arterial interventional chemotherapy has certain advantages. This article mainly reviews the application status and progress of interventional chemoembolization in advanced cervical cancer, and sorts out the application progress of interventional chemoembolization in advanced cervical cancer, in order to provide reference for clinical treatment of the disease.

参考文献/References:

[1]Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132. [2]Leathc A,Monk BJ.Twenty-first century cervical cancer management: A historical perspective of the gynecologic oncology group/NRG oncology over the past twenty years[J].Gynecologic Oncology,2018,150(3):391-397. [3]李恒,南巧玲,李淑梅,等.介入化疗栓塞与全身静脉化疗治疗宫颈癌的临床观察[J].甘肃医药,2018,37(2):136-138. [4]陈春林,刘萍.妇产科放射介入治疗学[M].北京:人民卫生出版社,2003:5-6.[5]马苗苗,普拉提·努尔别克,张泽高,等.单药顺铂与顺铂联合吉西他滨同步放化疗治疗中晚期宫颈癌的预后分析[J].中国肿瘤,2017,26(12):995-998.[6]张晓峰,赵维敬,杜静,等.宫颈癌术前动脉介入化疗栓塞与全身化疗的疗效比较[J].武警医学,2020,31(10):849-852.[7]李敏,梁攀,陈慧子.术前动脉介入化疗治疗早期巨块型宫颈癌的临床效果观察[J].青岛医药卫生,2022,54(3):161-165.[8]杨卉.术前子宫动脉介入化疗栓塞术对宫颈癌患者肿瘤切除率及生存质量的影响[J].河北医药,2017,39(23):3530-3533,3538.[9]陈志琴,高玉玲,李文洲.新辅助化疗前后局部晚期宫颈癌中VEGF-C、VEGFR-3表达及疗效的研究[J].中国医药科学,2020,10(12):201-204.[10]方梓羽,段慧,陈春林,等.中国大陆部分医院宫颈癌术前新辅助化疗情况大数据调查和分析[J].中国实用妇科与产科杂志,2018,34(1):100-105.[11]马益民,程靖辉,朱菊盼.基于患者为中心的介入治疗与放射治疗联合疗法在中晚期宫颈癌治疗中的效果分析[J].安徽医药,2018,22(5):889-893. [12]孙静莉.术前选择性子宫动脉化疗栓塞用于宫颈癌的临床疗效分析[J].实用癌症杂志,2018,33(3):493-496. [13]陆国权,周晓红,陈红,等.多西他赛联合顺铂化疗同步放疗治疗中晚期宫颈癌效果观察[J].山东医药,2016,56(38):83-84. [14]赵卫东.局部晚期宫颈癌术前化疗药物及方案的选择[J].中国实用妇科与产科志,2018,34(11):1203-1207.[15]Moore DH,Blessing JA,McQuellon RP,et al.Phase Ⅲ study of cisplatin with or without paclitaxel in stage ⅣB,Recurrent or Persistent Squamous cell Carcinoma of the Cervix:A Gynecologic Oncology Group study[J].Journal of Clinical Oncology,2004,22(15):3113-3119.[16]Park DC,Suh MJ,Yeo SG.Neoadjuvant paclitaxel and cisplatin in uterine cervical cancer:long-term results[J].International Journal of Gynecological Cancer,2009,19(5):943-947.[17]Ma L,Fisk JM,Zhang RR,et al.Eosinophilic dysplasia of the cervix:a Newlv recognized variant of cervical squamous intraepithelial neoplasia[J].Am J Surg Pathol,2004,28(11):1474-1484.[18]肖莉,万义增,王宝,等.宫颈上皮内瘤变及鳞癌组织中组蛋白去乙酰化酶1的表达及与HPV16/18感染的关系[J].中国医科大学学报,2015,44(5):464-467,471.[19]Zanotti S,Fisseler-Eckhoff A,Mannherz HG.Changes in the topological expression of markers of differentiation and apoptosis in defined stages of human cervical dysplasia and carcinoma[J].Gynecologic Oncology,2003,89:376-384.[20]王斌,张圳妙,全毅,等.宫颈癌根治术前介入化疗对手术疗效、肿瘤细胞凋亡、术后生活质量的影响[J].沈阳医学院学报,2021,23(3):221-224.[21]王惠霞,李淑红,赵宏燕.术前不同途径新辅助化疗对宫颈癌血管新生及细胞增殖的影响[J].海南医学院学报,2016,22(20):2463-2466.[22]王芳,霍彦,王宇全,等.HPV感染对宫颈癌细胞中自噬的影响[J].国际妇产科学志,2020,47(5):520-524,549.[23]甘露,龙卫红,李玢,等.子宫动脉介入化疗联合栓塞治疗前后宫颈癌组织miR-143和岩藻糖基转移酶Ⅳ表达及意义[J].中华实用诊断与治疗杂志,2017,31(11):1087-1089. [24]李连香,陈丽宏.宫颈癌新辅助化疗miRNA的差异表达[J].现代中西医结合杂志,2014,23(2):122-124,139.[25]杜宇,杨卫东,崔铱婕,等.宫颈癌介入化疗后患者EGFR蛋白表达变化及疗效分析[J].河北医药,2018,40(16):2445-2448. [26]冯艳,贺晶.G蛋白偶联受体30在宫颈癌组织中的表达及临床意义[J].解放军医药杂志,2016,28(10):50-53. [27]田志华,郝钢华,侯晓静,等.SAHA联合顺铂对裸鼠宫颈癌抑瘤作用及其机制[J].空军医学杂志,2015,31(3):158-161. [28]邓晰月,洪文旭,吴运妙,等.宫颈癌细胞株HeLa与正常宫颈细胞株Ect1/E6E7的微小RNA表达谱的差异[J].中国妇幼保健,2016,31(1):149-152.[29]程海燕,杨秀凤,马会清.宫颈癌介入化疗前后SDF-1和CXCR4表达及意义[J].齐鲁医学杂志,2015,30(2):135-137,140.[30]韩庆玲,文兰英,南云泽.子宫动脉介入化疗栓塞术在98例中晚期宫颈癌中的疗效观察[J].延边大学医学学报,2017,40(3):210-213.

相似文献/References:

[1]李菡旖.顺铂同步放化疗方案治疗中晚期宫颈癌的疗效[J].医学信息,2019,32(24):103.[doi:10.3969/j.issn.1006-1959.2019.24.034]
 LI Han-yi.Efficacy of Cisplatin Concurrent Chemoradiotherapy for Advanced Cervical Cancer[J].Journal of Medical Information,2019,32(12):103.[doi:10.3969/j.issn.1006-1959.2019.24.034]

更新日期/Last Update: 1900-01-01